KR20240006050A - 대사질환 치료를 위한 락토일 아미노산 - Google Patents

대사질환 치료를 위한 락토일 아미노산 Download PDF

Info

Publication number
KR20240006050A
KR20240006050A KR1020237041490A KR20237041490A KR20240006050A KR 20240006050 A KR20240006050 A KR 20240006050A KR 1020237041490 A KR1020237041490 A KR 1020237041490A KR 20237041490 A KR20237041490 A KR 20237041490A KR 20240006050 A KR20240006050 A KR 20240006050A
Authority
KR
South Korea
Prior art keywords
lac
phe
lactoyl
subject
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041490A
Other languages
English (en)
Korean (ko)
Inventor
조나단 롱
베로니카 리
스티븐 바닉
용 쉬
양 허
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
베이롤 칼리지 오브 메드신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티, 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티, 베이롤 칼리지 오브 메드신 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20240006050A publication Critical patent/KR20240006050A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237041490A 2021-05-04 2022-05-02 대사질환 치료를 위한 락토일 아미노산 Pending KR20240006050A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183868P 2021-05-04 2021-05-04
US63/183,868 2021-05-04
PCT/US2022/027261 WO2022235557A1 (en) 2021-05-04 2022-05-02 Lactoyl amino acids for the treatment of metabolic disease

Publications (1)

Publication Number Publication Date
KR20240006050A true KR20240006050A (ko) 2024-01-12

Family

ID=83932803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041490A Pending KR20240006050A (ko) 2021-05-04 2022-05-02 대사질환 치료를 위한 락토일 아미노산

Country Status (7)

Country Link
US (1) US20240189266A1 (https=)
EP (1) EP4313297A4 (https=)
JP (1) JP2024516969A (https=)
KR (1) KR20240006050A (https=)
CN (1) CN117769414A (https=)
AU (1) AU2022271191A1 (https=)
WO (1) WO2022235557A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240122888A1 (en) * 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of phenylalanine and lactate
CN116035217B (zh) * 2022-12-23 2023-08-04 暨南大学 一种具有减肥减脂作用的组合物与应用
WO2024192165A1 (en) * 2023-03-14 2024-09-19 The Board Of Trustees Of The Leland Stanford Junior University N-beta-hydroxybutyryl-amino acids and related compositions and methods
WO2025072489A2 (en) * 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2025184353A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating metabolic disorders
CN118795011B (zh) * 2024-06-28 2025-01-21 合肥工业大学 一种用于细胞代谢产物n-l-乳酰-l-苯丙氨酸的快速检测方法
CN119350175B (zh) * 2024-10-15 2026-03-17 广东药科大学 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159146A (zh) * 1995-07-26 1997-09-10 弗门尼舍有限公司 风味产品及其制备方法
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
WO2012054528A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies

Also Published As

Publication number Publication date
CN117769414A (zh) 2024-03-26
WO2022235557A1 (en) 2022-11-10
US20240189266A1 (en) 2024-06-13
EP4313297A4 (en) 2024-09-18
EP4313297A1 (en) 2024-02-07
JP2024516969A (ja) 2024-04-18
AU2022271191A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
KR20240006050A (ko) 대사질환 치료를 위한 락토일 아미노산
Yuan et al. Exercise‐induced α‐ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1‐dependent adrenal activation
Li et al. 7-Dehydrocholesterol dictates ferroptosis sensitivity
Huang et al. Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR/STAT3/IL-6 signaling
Okabe et al. Implications of altered NAD metabolism in metabolic disorders
Baek et al. Involvement of endoplasmic reticulum stress in myofibroblastic differentiation of lung fibroblasts
Zhang et al. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway
Mao et al. Ferroptosis: a potential bridge linking gut microbiota and chronic kidney disease
Roux et al. Endogenous glutamine decrease is associated with pancreatic cancer progression
Ceco et al. Metabolism and skeletal muscle homeostasis in lung disease
Zhang et al. The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis
Ma et al. HDAC5-mTORC1 interaction in differential regulation of ghrelin and nucleobindin 2 (NUCB2)/nesfatin-1
WO2024192165A1 (en) N-beta-hydroxybutyryl-amino acids and related compositions and methods
Yin et al. Nucleolin promotes autophagy through PGC-1α in LPS-induced myocardial injury
Lin et al. Homocysitaconate controls inflammation through reshaping methionine metabolism and N-homocysteinylation
Caioli et al. Baicalein reverts L-valine-induced persistent sodium current up-modulation in primary cortical neurons
Wang et al. New insights into lactate in exercise adaptations: does protein lactylation play a role?
Fu et al. Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction–associated steatotic liver disease progression
Fan et al. Adaptor protein APPL1 coordinates HDAC3 to modulate brown adipose tissue thermogenesis in mice
La Spina et al. Multiple mechanisms converging on transcription factor EB activation by the natural phenol pterostilbene
Liu et al. 3-Fucosyllactose Prevents Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota-Derived Pantothenate in Mice
CN112870358B (zh) 去泛素化酶usp20在降低胆固醇合成并改善代谢综合征中的用途
Zaidi et al. Functional Expression of γ–Amino Butyric Acid Transporter 2 in Human and Guinea Pig Airway Epithelium and Smooth Muscle
US20210267939A1 (en) Compositions and methods for treating nafld/nash and related disease phenotypes
WO2025184353A1 (en) Methods and compositions for treating metabolic disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250418

Comment text: Request for Examination of Application